Intratumoral Microbiota: an Emerging Force in Diagnosing and Treating Hepatocellular Carcinoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Oct 25

PMID 39453562

Authors

Huanxiang Liu

Jiahao Zhang

Yuye Rao

Shengjie Jin

Chi Zhang

Dousheng Bai

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) ranks among the most prevalent types of cancer in the world and its incidence and mortality are increasing year by year, frequently diagnosed at an advanced stage. Traditional treatments such as surgery, chemotherapy, and radiotherapy have limited efficacy, so new diagnostic and treatment strategies are urgently needed. Recent research has discovered that intratumoral microbiota significantly influences the development, progression, and metastasis of HCC by modulating inflammation, immune responses, and cellular signaling pathways. Intratumoral microbiota contributes to the pathologic process of HCC by influencing the tumor microenvironment and altering the function of immune system. This article reviews the mechanism of intratumoral microbiota in HCC and anticipates the future possibilities of intratumoral microbiota-based therapeutic strategies for HCC management. This emerging field provides fresh insights into early diagnosis and personalized approaches for HCC while holding substantial clinical application potential to improve patient outcomes and tailor interventions to individual tumor profiles.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim A, Zheng R . Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2021; 161:108-118. DOI: 10.1016/j.ejca.2021.11.023. View

Singal A, Lampertico P, Nahon P . Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72(2):250-261. PMC: 6986771. DOI: 10.1016/j.jhep.2019.08.025. View

Chen T, Zhang Y, Liu J, Rao Z, Wang M, Shen H . Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023; 13(12):e074348. PMC: 10759138. DOI: 10.1136/bmjopen-2023-074348. View

Raoul J, Forner A, Bolondi L, Cheung T, Kloeckner R, De Baere T . Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2018; 72:28-36. DOI: 10.1016/j.ctrv.2018.11.002. View

Yeh H, Chiang C, Yen T . Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol. 2021; 27(26):4104-4142. PMC: 8311541. DOI: 10.3748/wjg.v27.i26.4104. View

Rajapakse J, Khatiwada S, Akon A, Yu K, Shen S, Zekry A . Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions. Gut Microbes. 2023; 15(2):2240031. PMC: 10454000. DOI: 10.1080/19490976.2023.2240031. View

Guo C, Kong L, Xiao L, Liu K, Cui H, Xin Q . The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies. Cell Biosci. 2023; 13(1):188. PMC: 10571290. DOI: 10.1186/s13578-023-01135-y. View

Garrett W . Cancer and the microbiota. Science. 2015; 348(6230):80-6. PMC: 5535753. DOI: 10.1126/science.aaa4972. View

10.

Dominguez-Bello M, Godoy-Vitorino F, Knight R, Blaser M . Role of the microbiome in human development. Gut. 2019; 68(6):1108-1114. PMC: 6580755. DOI: 10.1136/gutjnl-2018-317503. View

11.

Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller L . The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020; 368(6494):973-980. PMC: 7757858. DOI: 10.1126/science.aay9189. View

12.

Liu N, Ma Q, Ge Y, Yi C, Wei L, Tan J . Microbiome dysbiosis in lung cancer: from composition to therapy. NPJ Precis Oncol. 2020; 4(1):33. PMC: 7730185. DOI: 10.1038/s41698-020-00138-z. View

13.

Ma Y, Qiu M, Wang S, Meng S, Yang F, Jiang G . Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules. Transl Oncol. 2021; 14(6):101050. PMC: 8022255. DOI: 10.1016/j.tranon.2021.101050. View

14.

Gao Z, Guo B, Gao R, Zhu Q, Qin H . Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015; 6:20. PMC: 4313696. DOI: 10.3389/fmicb.2015.00020. View

15.

Huang J, Wang J, Chai X, Li Z, Jiang Y, Li J . The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma. Microbiol Spectr. 2022; 10(5):e0098322. PMC: 9602924. DOI: 10.1128/spectrum.00983-22. View

16.

Sookoian S, Salatino A, Castano G, Landa M, Fijalkowky C, Garaycoechea M . Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut. 2020; 69(8):1483-1491. DOI: 10.1136/gutjnl-2019-318811. View

17.

Xue C, Chu Q, Zheng Q, Yuan X, Su Y, Bao Z . Current understanding of the intratumoral microbiome in various tumors. Cell Rep Med. 2023; 4(1):100884. PMC: 9873978. DOI: 10.1016/j.xcrm.2022.100884. View

18.

Qu D, Wang Y, Xia Q, Chang J, Jiang X, Zhang H . Intratumoral Microbiome of Human Primary Liver Cancer. Hepatol Commun. 2022; 6(7):1741-1752. PMC: 9234634. DOI: 10.1002/hep4.1908. View

19.

Komiyama S, Yamada T, Takemura N, Kokudo N, Hase K, Kawamura Y . Profiling of tumour-associated microbiota in human hepatocellular carcinoma. Sci Rep. 2021; 11(1):10589. PMC: 8134445. DOI: 10.1038/s41598-021-89963-1. View

20.

He Y, Zhang Q, Yu X, Zhang S, Guo W . Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med. 2023; 21(1):68. PMC: 9893660. DOI: 10.1186/s12967-023-03938-6. View